Logo
Hyaluronidase 1500 IU Box

Hyaluronidase 1500 IU Box

Misc (Generics)

Injectable enzyme (POM)
  • Described by UK aesthetic pharmacy sources as an UNLICENSED prescription Only medicine; prescribers assume full responsibility for its use, monitoring and follow Up.
  • Unlicensed products should only be used where an appropriate licensed alternative is not available, in line with MHRA and professional guidance on unlicensed medicines.
  • Use must comply with national medicines legislation, professional prescribing standards and local clinical governance policies.
  • Any aesthetic use (e.g. filler reversal) is off Label and should follow recognised evidence Based protocols and professional society guidelines.
Hyaluronidase 1500 IU powder for solution for injection/infusion

Description

Hyaluronidase 1500 IU Box contains multiple vials of hyaluronidase powder for solution for injection/infusion (typically 1500 IU per vial in 1 ml ampoule presentation). It is a prescription-only medicine used to increase tissue permeability by depolymerising hyaluronic acid in the extracellular matrix, thereby enhancing the dispersion and absorption of injected fluids (such as subcutaneous infusions and local anaesthetics) and promoting resorption of excess fluids and blood in tissues. In aesthetic practice it is also used off-label by qualified prescribers to dissolve hyaluronic acid dermal fillers when clinically indicated. The specific product referenced is supplied as an UNLICENSED medicine in the UK; as such, the prescriber assumes full responsibility for its use and for patient monitoring and follow-up care, and it should only be used where a suitable licensed alternative is not available.

Bnefits

  • Enhances permeation and dispersion of subcutaneous or intramuscular injections and subcutaneous infusions by breaking down hyaluronic acid in connective tissue.
  • Improves spread and absorption of certain local anaesthetics and other compatible injected drugs when combined according to product information and clinical guidelines.
  • Promotes resorption of excess tissue fluids and blood (e.g. in some haematoma or extravasation scenarios) where dispersal is clinically desired.
  • Provides a reversible mechanism for breaking down hyaluronic acid–based dermal fillers in cases of overcorrection, malplacement, lumps or certain complications, when used off-label by trained clinicians.
  • Acts locally and transiently at the injection site; the enzyme is subsequently inactivated or metabolised by the body.

Indications

  • Enhancing permeation of subcutaneous or intramuscular injections as described in relevant hyaluronidase product literature.
  • Facilitating dispersion and absorption of subcutaneous infusions (hypodermoclysis) where appropriate.
  • Improving the spread and effect of some local anaesthetic solutions when used in accordance with prescribing information.
  • Promoting resorption of excess fluids and blood in tissues (e.g. certain haematomas or extravasation events), where dispersal rather than localisation is required and supported by clinical guidance.
  • Off-label aesthetic use in the management of hyaluronic acid dermal fillers (e.g. overfilling, nodules, asymmetry or suspected vascular compromise), performed only by experienced prescribers following recognised protocols.

Composition

  • Active ingredient: Hyaluronidase 1500 International Units (IU) per vial (freeze-dried powder).
  • Excipients: brand-specific stabilisers and buffer salts (e.g. small amounts of amino acids such as tyrosine and other standard injectable excipients; exact qualitative and quantitative composition depends on manufacturer and should be checked in the supplied documentation).

Formulation

  • Pharmaceutical form: powder for solution for injection/infusion.
  • White, sterile freeze-dried powder intended to be reconstituted immediately before use.
  • Each vial contains 1500 IU of hyaluronidase, typically reconstituted to a 1 ml solution for injection or for mixing with compatible infusion or anaesthetic solutions, according to the specific product’s instructions for use.
  • Intended for parenteral administration by trained healthcare professionals only.

Packaging

  • Outer carton containing multiple vials of hyaluronidase 1500 IU powder (commonly supplied as multi-vial packs such as 5 or 10 vials per box, depending on the supplier).
  • Each glass vial contains 1500 IU hyaluronidase as a sterile freeze-dried powder, usually for reconstitution to 1 ml solution.
  • Package leaflet / product information included with clinical and pharmaceutical details.
  • Labelled as a prescription-only medicine (POM) and, in the context referenced, as an UNLICENSED product in the UK.

Usage

  • For use only by appropriately qualified prescribers and healthcare professionals familiar with injectable medicines and the management of potential adverse reactions.
  • Reconstitute each vial of 1500 IU hyaluronidase with an appropriate volume of sterile water for injections or normal saline immediately before use, following the specific instructions in the accompanying product documentation or relevant summary of product characteristics (SmPC).
  • Administer by the route and at the dose appropriate to the licensed or intended indication (e.g. mixed with subcutaneous infusion fluids, combined with local anaesthetics, or injected subcutaneously/intradermally for dispersal of fluids) strictly in line with clinical guidelines and local protocols.
  • In aesthetic off-label use for dermal filler management, dosing, dilution, injection depth and pattern should follow evidence-based protocols and professional consensus guidance, with particular care in high-risk anatomical areas.
  • Ensure that resuscitation equipment and emergency medications (including agents for managing anaphylaxis) are immediately available when administering hyaluronidase.
  • Patients should be counselled about potential risks, signs of allergic reactions and what to do in case of unexpected symptoms; appropriate monitoring after injection is required.
  • Unlicensed product use requires that the prescriber documents rationale, obtains informed consent and ensures careful follow-up and adverse event reporting where applicable.

Contraindications

  • Known hypersensitivity to hyaluronidase or to any of the excipients present in the specific product.
  • History of severe allergic or anaphylactic reactions to hyaluronidase or similar enzyme preparations.
  • Use in or around areas of active infection or severely inflamed skin unless the benefit clearly outweighs the risk and is justified by the prescriber.
  • Situations where increased tissue permeability and dispersion of a particular drug or fluid would be undesirable (e.g. some cytotoxic extravasations), according to local guidance and product information.
  • Caution or avoidance in patients with conditions where rapid fluid shifts may be hazardous, as directed by the prescriber and referenced product literature.
  • Not for self-administration by patients; not to be used without a clear indication determined by a qualified prescriber.

Adverse Effects

  • Injection-site reactions such as pain, redness, swelling, tenderness, itching or bruising.
  • Localised oedema or discomfort due to increased tissue permeability and fluid movement at the injection site.
  • Allergic reactions ranging from mild local hypersensitivity (e.g. rash, urticaria) to rare but serious systemic reactions, including anaphylaxis requiring emergency treatment.
  • Potential unintended enhanced dispersion of co-administered medicines if dosing and indications are not carefully considered, which could alter their expected local effect profile.
  • In aesthetic off-label use, over-treatment can lead to excessive breakdown of hyaluronic acid (including native HA and filler), resulting in loss of desired volume or contour changes.
  • Other adverse effects listed in the relevant SmPC or product information for licensed hyaluronidase preparations, which prescribers should consult before use.

Storage Conditions

  • Store in accordance with the specific storage instructions on the carton and package leaflet for the product supplied.
  • Typically stored in a cool, dry place away from direct light and excessive heat; some brands may specify storage below a certain temperature (e.g. below 25 °C).
  • Do not freeze unless explicitly indicated as acceptable by the manufacturer.
  • Keep vials in the original outer carton until time of use to protect from light and maintain identification and traceability.
  • Use reconstituted solution within the timeframe specified in the product information; discard any unused reconstituted solution appropriately.
  • Keep out of the sight and reach of children and do not use after the expiry date printed on the packaging.

Duration

The pharmacological action of hyaluronidase is rapid and transient; it temporarily increases tissue permeability and enhances dispersion and absorption of administered fluids over a period of minutes to several hours. Clinical effects such as reduction of tissue swelling or dispersion of injected solutions typically manifest within this timeframe, while long-term outcomes depend on the underlying indication and co-administered treatments.

Onset

Onset of action is usually rapid, with increased permeability and dispersion of injected solutions often observed soon after administration (from minutes up to the first few hours), depending on dose, site of injection, co-administered medications and tissue characteristics.

Browse more Injectable enzyme (POM)

Top Treatments

Top Cities in the UK